A Weidemann1, A Lovas1, A Rauch2, N Andreas1, J von Maltzahn1, M Riemann1, F Weih1,3. 1. Immunology, Leibniz Institute for Age Research - Fritz Lipmann Institute (FLI), Jena, Germany. 2. Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark. 3. Faculty of Biology and Pharmacology, Friedrich-Schiller-University Jena, Jena, Germany.
Abstract
BACKGROUND AND OBJECTIVE: Inflammation of adipose tissue (AT) is a central mediator of insulin resistance. However, the molecular mechanisms triggered by inflammatory cells are not fully understood. The aim of this study was to analyze the metabolic functions of lymphotoxin-β-receptor (LTβR)-mediated alternative NF-κB signaling in adipocytes and to reveal its effects on body weight and insulin sensitivity in vivo. METHODS: RelB(FatKO) mice and littermate controls were treated with LTβR agonistic antibody (α-LTβR) or a LTβR antagonist (LTβR:Ig fusion protein) after feeding a high-fat diet or standard diet. Mice were analyzed by insulin tolerance and glucose tolerance tests prior to analysis by necropsy and qRT-PCR of abdominal white adipose tissue. 3T3-L1 preadipocytes and mouse embryonic fibroblasts were used for differentiation and expression analysis after treatment with α-LTβR and differentiation to adipocytes. The molecular mechanism was elucidated by chromatin immunoprecipitation and combinatorial treatment with α-LTβR and tumor necrosis factor (TNF). RESULTS: RelB(FatKO) mice showed improved insulin sensitivity despite increased adiposity and adipocyte hypertrophy. LTβR-induced activation of p52-RelB in 3T3-L1 cells attenuated adipogenesis and modulated adipocyte functions via transcriptional downregulation of peroxisome proliferator-activated receptor γ (PPARγ). This LTβR-mediated pathway was synergistically regulated via a TNF-induced increase in p100 and RelB expression and nuclear translocation. CONCLUSIONS: Our data describe an anti-adipogenic action of LTβR signaling and a novel synergism of alternative and classical NF-κB signaling in the regulation of adipocytes. In conclusion, this strong synergism between the two NF-κB pathways shows a method to inhibit adipocyte differentiation and to improve insulin sensitivity and can be a potential target to treat metabolic disorders more efficiently than with other known drugs.
BACKGROUND AND OBJECTIVE: Inflammation of adipose tissue (AT) is a central mediator of insulin resistance. However, the molecular mechanisms triggered by inflammatory cells are not fully understood. The aim of this study was to analyze the metabolic functions of lymphotoxin-β-receptor (LTβR)-mediated alternative NF-κB signaling in adipocytes and to reveal its effects on body weight and insulin sensitivity in vivo. METHODS:RelB(FatKO) mice and littermate controls were treated with LTβR agonistic antibody (α-LTβR) or a LTβR antagonist (LTβR:Ig fusion protein) after feeding a high-fat diet or standard diet. Mice were analyzed by insulin tolerance and glucose tolerance tests prior to analysis by necropsy and qRT-PCR of abdominal white adipose tissue. 3T3-L1 preadipocytes and mouse embryonic fibroblasts were used for differentiation and expression analysis after treatment with α-LTβR and differentiation to adipocytes. The molecular mechanism was elucidated by chromatin immunoprecipitation and combinatorial treatment with α-LTβR and tumor necrosis factor (TNF). RESULTS:RelB(FatKO) mice showed improved insulin sensitivity despite increased adiposity and adipocyte hypertrophy. LTβR-induced activation of p52-RelB in 3T3-L1 cells attenuated adipogenesis and modulated adipocyte functions via transcriptional downregulation of peroxisome proliferator-activated receptor γ (PPARγ). This LTβR-mediated pathway was synergistically regulated via a TNF-induced increase in p100 and RelB expression and nuclear translocation. CONCLUSIONS: Our data describe an anti-adipogenic action of LTβR signaling and a novel synergism of alternative and classical NF-κB signaling in the regulation of adipocytes. In conclusion, this strong synergism between the two NF-κB pathways shows a method to inhibit adipocyte differentiation and to improve insulin sensitivity and can be a potential target to treat metabolic disorders more efficiently than with other known drugs.
Authors: J L Browning; I D Sizing; P Lawton; P R Bourdon; P D Rennert; G R Majeau; C M Ambrose; C Hession; K Miatkowski; D A Griffiths; A Ngam-ek; W Meier; C D Benjamin; P S Hochman Journal: J Immunol Date: 1997-10-01 Impact factor: 5.422
Authors: G Tiller; H Laumen; P Fischer-Posovszky; A Finck; T Skurk; M Keuper; U Brinkmann; M Wabitsch; D Link; H Hauner Journal: Int J Obes (Lond) Date: 2010-06-15 Impact factor: 5.095
Authors: Cécile Bénézech; Emma Mader; Guillaume Desanti; Mahmood Khan; Kyoko Nakamura; Andrea White; Carl F Ware; Graham Anderson; Jorge H Caamaño Journal: Immunity Date: 2012-08-30 Impact factor: 31.745
Authors: Calvin C Chan; Michelle S M A Damen; Pablo C Alarcon; Joan Sanchez-Gurmaches; Senad Divanovic Journal: J Interferon Cytokine Res Date: 2019-03-28 Impact factor: 2.607
Authors: B William Ogunkolade; Antonysunil Adaikalakoteswari; Shirleny Romualdo Cardoso; Rob Lowe; Nisha Patel; Vardhman Rakyan; Sarah Finer; Martin Wabitsch; Ponnusamy Saravanan; Gyanendra Tripathi; Elena Bochukova; Graham A Hitman Journal: Epigenetics Date: 2021-11-25 Impact factor: 4.861